14 studies on Gh igf 1 axis mechanism curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
**Clinicians managing TBI or SAH survivors should consider routine GH axis screening**, as hypopituitarism and aGHD are far more prevalent in this population than traditionally assumed. The **GHRP-2 test's <9 ng/mL cu…
**GHRP-2's secretagog efficacy is uniquely insensitive to the hormonal and metabolic factors that blunt GHRH-driven GH release**, including visceral adiposity and the IGF-1 / IGFBP axis. For clinicians and researchers…
**Clinicians managing thalassemia-related growth failure** should note that standard stimulation testing may miss subnormal ultradian GH secretion, meaning affected patients could benefit from secretagogue-based proto…
**MK-0677's entire hormonal efficacy — both IGF-I elevation and cortisol rise — is pituitary-gated**, meaning any context that compromises hypothalamic-pituitary function (severe illness, pituitary adenoma, prior radi…
**Systemic GH secretagogue use — including MK-0677 — does not elevate CNS IGF-1 or GH levels**, which has direct implications for researchers and clinicians who hypothesize that peripheral GH/IGF-1 elevation might pro…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
**The 84% IGF-1 elevation confirms MK-0677 reliably engages its target even in elderly, post-surgical patients** — a pharmacokinetically important signal for clinicians and researchers designing GH-axis interventions.…
**Clinicians and researchers** targeting age-related cardiovascular decline now have a cellular mechanism — EPC restoration via `IGF-1` — to anchor therapeutic protocols around GH secretagogues or direct IGF-1 interve…
**Elevated IGF-1 alone does not translate to clinically meaningful functional recovery** in frail elderly hip fracture patients — a finding that should temper enthusiasm for `GHSR` agonists in this population. The eme…
**Glucocorticoid users do not need to forgo ipamorelin co-administration out of concern that the steroid will block GH release** — this study directly demonstrates the GH axis remains responsive. For clinicians managi…
**Practitioners using ipamorelin or GHRP-6 to elevate IGF-1 should note that active or poorly-controlled type 1 diabetes may render these secretagogues incapable of raising IGF-1**, because the hepatic GH receptor pat…
**Weekly or biweekly dosing** replacing daily GHRH injections is a substantial practical advance for any GH-optimization protocol. Clinicians and researchers investigating GH axis restoration — whether for **GH defici…
**Continuous GHRH stimulation does not blunt GH pulsatility** — a concern that had been a theoretical barrier to long-acting GHRH therapeutics. For clinicians and researchers, this validates the mechanistic rationale …
**Identifying reliable serum biomarkers of GH action is a critical unmet need** both for anti-doping enforcement and for titrating GH replacement therapy in clinical practice. The linear IGF-1 correlation with the imm…